PDF
(Download)
|
- Boswellia (Boswellia serrata)
- Type 2 Diabetes
- Liver Function
|
Date:
12-15-2014 | HC# 061453-510
|
Re: Clinical Effect of Boswellia on Type 2 Diabetes Metabolic Parameters
Ahangarpour
A, Heidari H, Fatemeh RAA, et al. Effect of Boswellia
serrata supplementation on blood lipid, hepatic enzymes and fructosamine
levels in type2 [sic] diabetic
patients. J Diabetes Metab Disord.
2014;13(1):29. doi: 10.1186/2251-6581-13-29.
The
elevated blood glucose levels characteristic of type 2 diabetes mellitus (T2DM)
are associated with hyperlipidemia and increased free fatty acid oxidation, which
cause damaging fatty deposits in the liver. The gum resin of boswellia (Boswellia serrata) has been found to reduce
blood glucose in diabetic rats and blood glucose levels in patients with T2DM.1
Animal studies have also shown that boswellia has significant antioxidant and
hypolipidemic properties. However, no studies have reported on the hypolipidemic
effects of boswellia or its effect on liver biomarkers in humans with T2DM. The
present study was performed to evaluate the hypolipidemic effect of boswellia
on patients with T2DM. The power calculation for α=0.05 and 90% power was 60
patients.
Patients
(n = 60) aged 30-48 years with T2DM for > 4 years and a fasting blood
glucose of 140-250 mg/dl participated in this study conducted at Ahvaz
Jundishapur University of Medical Sciences; Ahvaz, Iran. Patients were excluded
if they had hepatic cirrhosis, chronic kidney disease, active proliferative
diabetic retinopathy, congestive heart failure, myocardial infarction within 6
months, or were pregnant or lactating women. Patients were instructed not to
modify their diet or exercise routine. Patients taking oral hypoglycemic agents
were instructed not to change their medication during the study. Half of the patients
received 900 mg/day boswellia gum resin in 3 divided doses for 6 weeks, and
half were an untreated control group. The boswellia was purchased from local
markets in Ahvaz, Iran and authenticated by the Department of Botany at Ahvaz
Jundishapur University. The authors do not describe how the boswellia was
prepared.
Blood
was drawn at baseline and study end to evaluate triglycerides (TG), total
cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein
(LDL), very-low-density lipoprotein (VLDL), serum glutamic-pyruvic transaminase
(SGPT, also known as alanine aminotransferase [ALT]), serum glutamic-oxaloacetic
transaminase (SGOT, also known as
aspartate transaminase [AST]), and fructosamine. The liver enzymes SGPT
and SGOT are commonly used as liver function biomarkers. Fructosamine is used
as a measure of glycosylated proteins, an indicator of short term (1-2 weeks)
changes in blood glucose. There were no significant differences between groups
at baseline.
Compared
with baseline, the boswellia group had a significant increase in HDL (P <
0.05) and a significant decrease in blood cholesterol (P < 0.05), LDL (P
< 0.05), fructosamine (P < 0.05), SGPT (P < 0.001), and SGOT (P <
0.01) after 6 weeks of treatment. However, there were no significant changes in
TG or VLDL compared to baseline. In the control group, only HDL significantly
increased (P < 0.01) compared to baseline. The authors suggest that the
improvements in the boswellia group may be attributed to its hypoglycemic,
hypolipidemic, and antioxidant properties. No adverse effects or serious
herb-drug interactions were reported.
Compared
with the control, the boswellia group had a significant improvement in VLDL (P
< 0.05), TG (P < 0.05), TC (P < 0.01), and SGOT (P < 0.01) after 6
weeks. However, in contrast to the baseline comparisons, there were no
significant changes in HDL, LDL, SGPT, or fructosamine in the boswellia group compared
to the control.
The
authors do not comment on these anomalies, nor the significant HDL increase
from baseline in the control group only. They do not report the SGPT:SGOT
ratios which are an important diagnostic for fatty liver.
The
authors conclude that consumption of 900 mg/day boswellia may provide "a
safe and effective means to decrease the risk factors associated with type2 [sic] diabetic subjects" and that
the regular consumption of boswellia may help maintain "fructosamine
levels, hepatic enzyme activities, and lipid profiles close to normal levels.
However, more extensive pharmacological experiments are required."
Acknowledged limitations of the study are the lack of controls for diet,
exercise, and diabetes patient education from outside sources.
—Heather
S. Oliff, PhD
Editorial Comment:
It is shameful that
the peer reviewers and editor(s) of the Journal
of Diabetes and Metabolic Disorders approved this article for publication. The
contorted grammar is a formidable barrier to objective scientific review. To
wit, "However in spite of distinctive improvement of serum
triglyceride and VLDL levels of type2 [sic]
diabetic patients after supplementation with Boswellia serrata in our study, significant difference in our study
did not detect varying levels after 6 weeks. … May be grounds for
non-significant differences in the factors mentioned can cause in type 2
diabetes."
Reference
1Ahangarpour
A, Akbari Fatemeh Ramezani A, Heidari H, et al. The effect of Boswellia serrata on blood glucose,
insulin level and insulin resistance in type 2 diabetic patients. Daneshvar. 2013;20(103):11-18.
|